Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.23 (
MMP
)
4,246
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The function of the androgen-regulated
homeobox protein NKX3.1
in prostate cancer is controversial.
NKX3.1
is necessary for correct prostate development and undergoes frequent allelic loss in prostate cancer. However, no mutations occur in the coding region and some particularly aggressive cancers over-express the protein. Nevertheless
NKX3.1
is often referred to as candidate tumor suppressor gene. Recent findings suggest a function in protection against oxidative damage involved in prostate carcinogenesis. Thus
NKX3.1
may act differently at various stages of prostate cancer. Unlike a classical tumor suppressor
NKX3.1
is up-regulated by androgens and down-regulated by phytoestrogens. In this study we performed RNAi based functional analysis by knocking down
NKX3.1
expression in LNCaP prostate cancer cells and analyzing the impact of
NKX3.1
on gene expression and cell proliferation. Knock-down of
NKX3.1
evoked a massive down-regulation of
NKX3.1
expression, followed by reduction in mRNA expression of the androdrogen receptor (AR) and the insulin-like growth factor receptor (IGF-1R). Western blot analysis showed strong decreases of
NKX3.1
, AR, and IGF-1R protein expression. Concomitantly, cell proliferation decreased and expression of prostate-specific antigen (PSA) mRNA and its secretion were diminished, whereas expression of IGF binding protein 3 (IGFBP-3) and
MMP
tissue inhibitor 3 (TIMP-3) was up-regulated. In tumor cells not deprived of
NKX3.1
expression this gene still has a function which might differ from its role in prostate development and carcinogenesis.
NKX3.1
knock-down altered the expression of genes highly relevant in prostate cancer cell proliferation and apoptosis. In LNCaP
NKX3.1
most probably plays the role of an androgen-regulated transcription factor whose down-regulation is paralleled by anti-proliferative and pro-apoptotic effects. Since
NKX3.1
can regulate AR expression it may become a target for interference in hormone refractory prostate carcinoma.
...
PMID:Functional analysis of NKX3.1 in LNCaP prostate cancer cells by RNA interference. 1836 Jul 15